Bristol Myers Squibb Company $BMY Position Reduced by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 25.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,716,740 shares of the biopharmaceutical company’s stock after selling 588,083 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned 0.08% of Bristol Myers Squibb worth $107,125,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Primecap Management Co. CA bought a new stake in shares of Bristol Myers Squibb in the second quarter worth $1,436,115,000. Legal & General Group Plc acquired a new position in Bristol Myers Squibb during the second quarter worth $980,862,000. BlackRock Inc. grew its position in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp grew its position in Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in Bristol Myers Squibb by 153.8% in the first quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company’s stock valued at $540,393,000 after purchasing an additional 5,399,407 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on BMY. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research report on Wednesday, August 5th. Cantor Fitzgerald decreased their target price on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday, October 8th. Daiwa Securities Group upped their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, Roth Capital started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $64.88.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Trading Up 4.7%

Shares of Bristol Myers Squibb stock opened at $59.34 on Thursday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a 50-day moving average of $63.72 and a 200-day moving average of $60.28. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The stock has a market cap of $121.22 billion, a PE ratio of 13.07, a PEG ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.70 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Pipeline progress provided the main catalyst. Bristol Myers reported favorable Phase 3 results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including improved progression-free survival. The data may support upcoming regulatory discussions and strengthen the company’s growth outlook as older blockbuster drugs face competitive pressure. What Could Bristol Myers Squibb BMY Two Phase 3 Wins Change?
• Positive Sentiment: Analyst support remains a tailwind. Truist Financial maintained its Buy rating on BMY, signaling confidence in the company’s pipeline and valuation. Bristol Myers’ relatively low earnings multiple and sizeable dividend yield may also attract income-oriented investors. Truist Financial Sticks to Its Buy Rating for Bristol Myers Squibb
• Neutral Sentiment: Admilparant results were characterized inconsistently. Reports described the Phase 3 idiopathic pulmonary fibrosis data as either positive or mixed, with favorable efficacy and safety observations but some limitations that could affect regulatory expectations. The conflicting interpretation makes the drug a potential opportunity but not yet a clear near-term catalyst. BMY Reports Mixed Phase III Trial Results
• Neutral Sentiment: Investor attention is elevated ahead of quarterly earnings. BMY is scheduled to report third-quarter results later this month, with analysts expecting a single-digit decline in earnings. Recent trial news and the stock’s strong longer-term performance have increased focus on whether results and guidance can support the valuation. Bristol Myers Squibb Quarterly Earnings Preview
• Negative Sentiment: Wells Fargo reduced its price target from $65 to $60 and kept an Equal Weight rating. The lower target reflects limited perceived upside and highlights ongoing concerns about earnings growth, patent-related pressure and the need for newer medicines to replace aging blockbusters. Wells Fargo Lowers Bristol Myers Squibb Price Target

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.